Cite
MLA Citation
David Reardon et al.. “ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM).” Neuro-oncology, vol. 20, n.d., p. vi10. http://access.bl.uk/ark:/81055/vdc_100095477767.0x00001d